Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited revenues of $167.5 million for the third quarter of 2022, compared with $127.7 million for the third quarter of 2021. The company’s revenues include net product sales of EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and the iovera° system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc.
https://finance.yahoo.com/news/pacira-biosciences-reports-preliminary-third-120000911.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.